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NeuropeptideToward twin goals of identifying molecular factors in brain injured by ischemic stroke, and the effects of neuro-
peptide pituitary adenylate-cyclase activating polypeptide (PACAP) on the ischemic brain, we have established
the permanent middle cerebral artery occlusion (PMCAO) mouse model and utilized the Agilent mouse whole
genome 4 × 44 K DNA chip. PACAP38 (1 pmol) injection was given intracerebroventrically in comparison to a
control saline (0.9% NaCl) injection, to screen genes responsive to PACAP38. Two sets of tissues were prepared,
whole hemispheres (ischemic and non-ischemic) and infract core and penumbra regions at 6 and 24 h. In this
study, we have detailed the experimental design and protocol used therein and explained the quality controls
for the use of total RNA in the downstreamDNAmicroarray experiment utilizing a two-color dye-swap approach
for stringent and conﬁdent gene identiﬁcation published in a series of papers by Hori and coworkers (Hori et al.,
2012–2015).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).SpeciﬁcationsOrganism/cell
line/tissueMus musculusStrains(s) Brain (hemisphere/ischemic regions/non-ischemic regions)
Sequencer or
array typeAgilent whole mouse genome microarray G4122FData format Raw data: TXT ﬁle, Normalized data: TXT
Experimental
factorsCerebral ischemia; permanent middle cerebral artery
occlusion; neurological grade; ipsilateral hemisphere,
non-injected; contralateral hemisphere, injected with saline
or PACAP38; time of ischemia; dissection of brains; infract
core and penumbra regions; total RNA extraction; RT-PCRConsent Animal care and experimental procedures approved by
Institutional Animal Care and Use Committee of Showa
University (School of Medicine), Tokyo, Japan.ional Initiatives, University of
an. Tel.: +81 90 1853 7875.
wal),
tama Medical University, 38
495, Japan.
. This is an open access article underDirect link to deposited data
Deposited data can be foundhere: GSE28201 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE28201), GSE37565 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37565), and GSE62884
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62884).
Data, experimental design, materials and methods
Generation of the permanent middle cerebral artery occlusion model
(PMCAO)
Brain ischemia, also termed cerebral ischemia or ischemic stroke, is a
major health problem worldwide [1]. Extremely debilitating to the
brain tissues, it is the third most common cause of death after heart at-
tack and cancer. The permanent middle cerebral artery occlusion
(PMCAO) model was used over the transient MCAO, due to the avoid-
ance of reperfusion injury in our research model aimed at providing
new insight into the PACAP38 neuroprotective effects in the mouse
brain [2–6]. PMCAO was performed on male mice (C57/BL6J), and the
results of the procedure were monitored by dissecting whole brainsthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
The permanentmiddle cerebral artery occlusion (PMCAO) experimentalmousemodel and the effect of PMCAO (ischemia), PACAP38 and saline treatments.Mousewere selected random-
ly based on neurological grade (NG) 1 and 2 but not 0 and 3 for sampling.
Mouse tail no. Body weight before operation (g) Neurological grade (NG)
PMCAO injected normal saline, and decapitated after 6 h
1 to 14 26.78, 26.54, 24.4, 30.64, 30.58, 25.93, 22.87, 22.53, 25.97, 23.47,
24.43, 23.15, 22.21, 23.00
2, 1, 2, 1, 0, 2, 2, 3, 2, 2, 0, 2, 0, 2
PMCAO injected normal saline, and decapitated after 24 h
1 to 17 26.44, 26.93, 26.65, 24.64, 25.85, 25.98, 26.71, 24.15, 22.55, 22.82,
23.64, 22.51, 23.05, 24.44, 23.87, 23.54, 23.60
2, 2a, 1, 3, 1a, 1, 1, 1, 0, 1, 2, 0, 3, 2, 2, 3, 3
PMCAO injected PACAP38, and decapitated after 6 h
1 to 6 23.78, 24.72, 24.33, 24.57, 25.17, 23.89 2, 1, 2, 1, 1, 2
PMCAO injected PACAP38, and decapitated after 24 h
1 to 7 25.92, 26.84, 26.52, 25.53, 23.00, 23.29, 23.91 1, 1, 1, 1, 2, 3, 2
Sham injected normal saline, and decapitated after 6 h
1 to 5 25.70, 24.27, 28.19, 26.96, 27.03 0, 0, 0, 0, 0
Sham injected normal saline, and decapitated after 24 h
1 to 5 24.15, 25.17, 25.99, 25.28, 25.90 0, 0, 0, 0, 0
Sham injected PACAP38, and decapitated after 6 h
1 to 5 25.06, 25.93, 25.82, 24.88, 26.34 0, 0, 0, 0, 0
Sham injected PACAP38, and decapitated after 24 h
1 to 5 23.93, 24.48, 25.40, 24.04, 25.48 0, 0, 0, 0, 0
a Indicates dead mouse.
149M. Hori et al. / Genomics Data 3 (2015) 148–154and visualizing the extent of ischemia. More than 80% of the mice sur-
vived the PMCAO procedure. Post-PMCAO, the effect of neuropeptide
pituitary adenylate-cyclase activating polypeptide 38 (PACAP38)Fig. 1. Expression of positive control genes, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) a
graphically for Gapdh and beta-actin mRNA relative abundance. Each gene was analyzed at
quantiﬁcation is presented. B, The expression of these two genes is given by the expressed lev
the Agilent microarray analysis software. Total RNA was extracted from the whole hemispher
6 and 24 h. PACAP38 was the treatment and saline served as the control (sham). Semi-quantit
and regimes, quality control of total RNA, and semi-quantitative RT-PCR and gene expression dtreatment (injection was performed intracerebroventrically) was ex-
amined in mouse; saline injection was used as a control [2–6]. The
aim was two-fold: ﬁrst, to provide a detailed ischemia-relatednd beta-actin, under RT-PCRandDNAmicroarray experiments. A, RT-PCR results presented
least twice as independent PCR reactions, and the representative data post-PCR band
el of probe signal intensity in Cy3 and Cy5 labels, following the Feature Extraction step in
e (hemisphere) and ischemic core and penumbra in the ipsilateral (right) hemisphere at
ative RT-PCR and DNA microarray analysis was performed as discussed in Sampling sites
ata.
150 M. Hori et al. / Genomics Data 3 (2015) 148–154transcriptome in mouse model, and second, was to explore the neuro-
protective effects of PACAP38 via gene inventories speciﬁc to PACAP38
effect and screening out the molecular factors and networks/pathways
being activated therein. The reason for using, DNA microarray technol-
ogy – one of the breakthrough technologies in experimental molecular
biology – was that it allows us to quickly observe the expression of
tens of thousands of genes in parallel in a single experiment. To be em-
phasized, this seemingly “quick” data is the product of a good experi-
ment design, planning, sampling of tissues and proper storage, and
quality control of the total RNA prior to the use of the microarray chip
itself.
In order to achieve the above objectives, two basic approaches were
taken that involved using hemispheres, ipsilateral containing the ische-
mic or infract core (called hereafter IC), penumbra (called thereafter
P) and non-ischemic regions, and contralateral (non-ischemic) in the
ﬁrst set of experiments with or without PACAP38 treatment, and the
second involving dissection of speciﬁc regions in the ischemic hemi-
sphere, namely the IC and the P. Themodel is described in [2–6] and is-
chemia was conﬁrmed by not only visual observation of the dissected
brains but also by triphenyltetrazolium chloride (TTC) staining [7].Fig. 2. Expression level of the beta-actin gene, by expressed level of probe signal intensity in Cy3
and ischemic core and penumbra in the ipsilateral (right) hemisphere at 6 and 24 h under PACA
labels, Cy3 and Cy5 under Sham, PMCAO inhemisphere and saline and PACAP38 treatments for
of 2 chips each. DNA microarray was performed as in Fig. 1.The gene expression data from these studies on hemispheres and
speciﬁc regions (IC and P) were deposited in the Gene Expression Om-
nibus (GEO) database under accession numbers GSE28201 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28201) [2,3],
GSE37565 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE37565) [4], and GSE62884 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE62884) [5,6].
Sampling sites and regimes, quality control of total RNA, and semi-
quantitative RT-PCR and gene expression data
The mouse exhibiting neurological grades G1 and G2 were used for
all experiments (Table 1) post PMCAO or after PACAP38 test solution in-
jection over a saline control [2–6]. We followed all animal care and ex-
perimental procedures under approval by the Institutional Animal Care
and Use Committee of Showa University (School of Medicine), Tokyo,
Japan. Two time points were selected, 6 h and 24 h post-PMCAO [2–6]
for sampling of the hemispheres and speciﬁc regions (IC and P), which
were immersed immediately post-dissection in liquid nitrogen and
thereafter transferred to a −80 °C deep freezer. The samples wereand Cy5 labels under DNAmicroarray experiment in thewhole hemisphere (hemisphere)
P38 and saline (sham) treatments. Ten probes for the beta-actin gene are plotted for both
both ischemic core and penumbra for speciﬁc regionsmicroarray experiments using a total
151M. Hori et al. / Genomics Data 3 (2015) 148–154individually ground in liquid nitrogen to prepare very ﬁne powders for
subsequent downstream gene expression analyses [2–6] and proteomic
analysis as required [4]. Prior to each DNAmicroarray analysis, the total
RNA, extracted using an optimized protocol based on the QIAGEN
RNeasyMini Kit (QIAGEN, Germantown,MD, USA) quantity and quality
was measured spectrophotometrically with NanoDrop (Thermo Scien-
tiﬁc, Wilmington, DE, USA) and re-conﬁrmed using formaldehyde-
agarose gel electrophoresis [2–6,8,9]. Brieﬂy, the obtained total RNA
quality measurements revealed good quality as demonstrated by the
A260/280 values N 1.8, A260/230 N 1.8; in our experiments, we always aim
for a higher value of more than 2.0 to 2.3 [2–6]. Furthermore, the total
RNAwas obtained in optimum quantity of N300 ng/μl. Following the vi-
sualization for conﬁrming pre-experimental integrity of the total RNAFig. 3. Intensity scatter plot of the two colors/chips. Upper-most two graphs show the raw data
genes plotted on each graph represent all the genes on the chip, chip 1 and chip 2, which were
cut-off for chip 1 and chip 2 has an up-regulated and down-regulated fold ratio of greater than o
by sky blue color); the blank vertical (for chip 1) and horizontal (chip 2) spaces between the sky
place (selection), the genes showing an up-regulated fold-change in chip 1 (pink) need to sh
regulations (pink). Then, the lower-most two graphs show the dye-swap scatter plots which r
red; common down-regulated ≦0.75 are in blue) based on the chip 1 and chip 2 data analyses
expression values are provided.subunits by gel electrophoresis, an additional step comprised of cDNA
synthesis was used for examining the quality of the synthesized cDNA
by determining the expression of genes glyceraldehyde 3-phosphate de-
hydrogenase (Gapdh) and beta-actin as positive controls. This was done
by RT-PCR (AfﬁnityScript QPCR cDNA Synthesis Kit; Stratagene, Agilent
Technologies, La Jolla, CA, USA and Emerald Amp PCR Master Mix;
TaKaRa Shuzo, Shiga, Japan) on a Thermal Cycler (Applied Biosystems,
Tokyo, Japan). Moreover, only gene-speciﬁc primers were used and
whose sequences are shown in the articles [2–6]. Post-electrophoresis,
the PCR products were visualized and quantiﬁed using a ChemiDoc
XRS+ imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
All the steps followed in sequence provided conﬁdence that we had
the best quality total RNA for use in the DNA microarray chip. As a lastat 6 and 24 h, Sham × PMCAO. Each spot on the graph refers to a single gene probe. The
used for dye-swap analysis as shown in the center four graphs (in dotted-line boxes). The
r equal to 1.5 (genes indicated bypink color) and less than or equal to 0.75 (genes indicated
blue andpink colors represent theno change in expression genes. For thedye-swap to take
ow a corresponding down-regulated value in chip 2 (blue) and vice versa for the down-
eveal reliable/conﬁdent gene expression selected (common up-regulated ≧1.5-fold are in
as described above. Genes with similar expression are on the diagonal; log-transformed
152 M. Hori et al. / Genomics Data 3 (2015) 148–154step, the Agilent mouse whole genome 4 × 44 K (G4122F) DNA slide
(composed of 4 chips on one slide)was used for themicroarray analysis,
which was performed according to the Agilent instructions (Agilent
Technologies, Santa Clara, CA, USA) and detailed in our publications
[2–6,8,9]. As alsomentioned below, our DNAmicroarray analysis exper-
iment is based on the two-color dye-swap approach [10]. Microarray
and sample annotation data were deposited in the Gene Expression
Omnibus (GEO) database under accession numbers GSE28201 [2,3],
GSE37565 [4], and GSE62884 [5,6].
Gene expression analysis comparison between RT-PCR and DNA
microarray experiment design (dye-swap) using positive controls
The ﬁrst quality control step presented itself in examining the ex-
pression of two genes, Gapdh and beta-actin normally used as house-
keeping genes or positive control genes by RT-PCR for all samples
used in the study; we prefer to use the latter terminology [11]. Fig. 1
compares the expression of these two control genes using the RT-PCRFig. 4. Expression of two differentially expressed genes, interleukin 6 (Il6) and brain-derived neur
PCR. A, Expression of Il6 and Bdnf genes by expressed level of probe signal intensity with Cy3 an
abundance. Total RNA was extracted from the whole hemisphere (hemisphere) and ischemic
treatment and saline served as the control (sham). DNA microarray analysis and RT-PCR wereanalysis (A) and the dye-swap based DNA microarray experiment
(B) for each sample, control and treatment in whole hemisphere and
speciﬁc regions of IC and P, at both 6 and 24 h time points. To note, for
RT-PCR each gene expression (Gapdh and beta-actin) analysis is per-
formed at least twice as independent PCR reactions (at different cycles
for avoiding taking the data at a plateau) and electrophoresis on gel
for each cDNA generated/sample [2–6], and a representative data is pre-
sented in Fig. 1A. Similarly, the probe signal intensity level is for a single
probe each for the two genes on the DNA microarray chip (Fig. 1B).
Comparing these representative data, some variation of gene expression
can be seen in the groups at 6 or 24 h time points, however, the expres-
sion of these genes did not dramatically vary, rather showed almost
similar expression levels between the RT-PCR based analysis and the
microarray experiment. In particular, similar expression levels (probe
signal intensity)were seenwith Cy3 andCy5 labels. Thus the expression
of positive control genes normally used in our research, and other stud-
ies, in general, are quite stable over all sample conditions and times.
Based on this analysis, not only the stable expression of some positiveotrophic factor (Bdnf), under DNAmicroarray experiment and subsequent validation by RT-
d Cy5 labels. B, RT-PCR results are presented graphically for these two genesmRNA relative
core and penumbra in the ipsilateral (right) hemisphere at 6 and 24 h. PACAP38 was the
performed as in Fig. 1.
153M. Hori et al. / Genomics Data 3 (2015) 148–154control genes but also the quality of synthesized cDNA was established.
Moreover, these gene expressions were also found to be stable under
the employed DNA microarray approach, namely dual-color and dye-
swap. Furthermore, to check if the expression level on the microarray
slide is similar across all probes plotted on the microarray chip, we ex-
amined the Cy3 and Cy5 label associated expression for all 10 probes
for the beta-actin gene as an example, in the whole hemisphere and IC
and P regions at both 6 h and 24 h time points (Fig. 2). Results showed
a good correlation between the Cy3 and Cy5 label expression points
across the 1.5-fold change ratio. This further conﬁrms the data present-
ed in Fig. 1, indicating that the gene expression for positive controls is
stable across samples and also individual probes used in a DNAmicroar-
ray design, and that can be compared with the RT-PCR-based analysis
method.Hybridization, normalization, and scatter plot distribution of inten-
sity values
Fluorescently labeled targets of control (sham/saline) as well as
treatments (PACAP38) were hybridized to the same microarray slide
with 60-mer probes. Selection of differentially expressed genes was
performed in a way that a gene up-regulated in chip 1 (Cy3 label for
sham and Cy5 label for PMCAO) was down-regulated in chip 2 (Cy5
label for sham and Cy3 label for PMCAO) (Fig. 3). A similar data were
presented for the PACAP38 versus sham (saline) treatments for the IC
and P regions (Supplementary Figs. 1 and2). The genes thatwere select-
ed thus had a higher conﬁdence, butwere less than the numbers obtain-
ed by using just one dye orientation. As also elegantly explained by
Dombkowski and co-workers in 2004, dye orientation has a signiﬁcant
inﬂuence on the measurements and inferences of differential gene ex-
pression most probably due to the labeling method, and further sug-
gesting that until dye bias effects can be explained the dye-swap
approach is important in the DNA microarray reference designs [10].
This still stands true today. Hybridization andwash processes were per-
formed according to the manufacturer's instructions, and hybridized
microarrays were scanned using an Agilent Microarray scanner
G2565BA or G2505C (Agilent Technologies). For the detection of signif-
icant differentially expressed genes between control and treated sam-
ples each slide image was processed by Agilent Feature Extraction
software (version 9.5.3.1 or 11.0.1.1, Agilent Technologies). The Feature
Extraction algorithms have been developed to reduce systematic errors
arising from labeling bias, irregular feature morphologies, mismatched
sample concentrations and cross hybridizations [12]. By this program,
the Cy3 and Cy5 signal intensities of whole probes are measured. Dye-
bias tends to be signal intensity dependent therefore the software
selects probes using a set by rank consistency ﬁlter for dye-
normalization. Said normalization is performed by LOWESS (locally
weighted linear regression) which calculates the log ratio of dye-
normalized Cy3- and Cy5-signals, as well as the ﬁnal error of log
ratio. The statistical signiﬁcance of the log ratio values obtained for
individual microarray probes is calculated using the “most conserva-
tive error model” default function of the Feature Extraction software,
by which both a propagated and a universal error model are evaluat-
ed, and the higher (more conservative estimate of error) p-value of
two error models is reported [13,14; Agilent Technologies]. The
propagated error model measures the error on the log ratio by prop-
agating the pixel-level error from calculations made in the analysis
(i.e., raw signal and background subtraction), whereas the universal
error model measures the expected error between the red and green
channels using the additive and multiplicative errors (Agilent Tech-
nologies). In these analyses, the threshold of signiﬁcant differentially
expressed genes was b0.01 (for the conﬁdence that the feature was
not differentially expressed). Additionally, the erroneous data gen-
erated due to artifacts were eliminated before data analysis by the
software.Validation of DNA microarray data using RT-PCR-based analysis of
interleukin 6 (Il6) and brain-derived neurotrophic factor (Bdnf)
gene expressions
Two differentially expressed genes, namely Il6 and Bdnf, as examples
in the PMCAO (Il6) and PACAP38 inﬂuenced (Bdnf) experiments were
examined and compared for their expression levels between themicro-
array experiment (Fig. 4 A) and RT-PCR (Fig. 4 B). A very good correla-
tion was seen between these two experiments for both Il6 and Bdnf. A
slight discrepancy was seen the case of the Bdnf gene, in the ischemic
core region sample at 6 h, where a slight increase in expression under
the microarray experiment (cut-off of greater than 1.5 fold) could not
be conﬁrmed by the RT-PCR analysis; it may be dependent on the
probe design used for RT-PCR or the only slight induction seen at 6 h
under the microarray data. Nevertheless, from this analysis as also in
Fig. 1 for positive control genes, a good correlation between the Cy3
andCy5 values from themicroarray experiment could be seen. These re-
sults not only show the importance of a validation step using an inde-
pendent method of gene expression analysis but also show that the
dye-swap approach-based screening of gene expressions is a reliable in-
dicator of the effect of the treatment being performed.
Discussion
We described here unique datasets of i) ischemia-related genes and
ii) genes potentially related to the neuroprotective effects of the neuro-
peptide PACAP38 from the brains of PMCAO model mouse. Each of the
three datasets is composed of genome-wide gene expression measured
using the Agilent Gene Expression Microarray platform using the dye-
swap approach (Agilent Technologies). We showed that the brain re-
sponse to ischemia can be evaluated at the level of the gene, genome-
wide, and presented the ﬁrst ischemia-related transcriptome analysis
of themouse brain in a series of studies using the Agilent DNAmicroar-
ray chip using both ipsilateral and contralateral hemispheres. Further-
more, as our primary interest is to clarify the role of the neuropeptide
PACAP38 in protecting or as a therapy for brain ischemia, we have
also comprehensively analyzed the brain responses in ischemic brain
after treatment (PACAP38) over saline (sham). It is our idea that these
large numbers of gene inventories obtained will provide a strong basis
for further research into not only understanding the ischemic brain
but also in pinpointing gene candidates potentially involved in mediat-
ing the neuroprotective effect of PACAP38.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2015.01.007.
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